04-75A50126R00001_RFP Att 3 Vendor Production Facilities.xlsx

This file is a vendor production facilities template designed for use in response to RFP #75A50126R00001 for the BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response Program. The template is divided into two primary sections: Bulk Production and Formulation/Fill-Finish. The Bulk Production section requires vendors to identify validated bulk manufacturing sites and lines, specify vaccine components (antigen only, adjuvant only, co-formulated antigen and adjuvant, or other), document final bulk container types and sizes, report target fill volumes, and state the maximum dose quantity that can be produced within a 180-day timeframe. The Formulation/Fill-Finish section requires vendors to identify validated formulation and fill-finish sites and lines, specify final fill presentation types (multi-dose vials, single-dose vials, pre-filled syringes, sprayers, etc.) and sizes, report target fill volumes, state maximum dose quantity production capacity within 180 days, and indicate whether fill-finish lines are used for other commercial products.

This template serves as an attachment to the broader RFP and functions as a data collection instrument to assess vendor manufacturing capabilities and capacity. Vendors must complete the template to demonstrate their ability to produce influenza vaccines and related components in support of pandemic preparedness efforts. The information gathered through this template will help BARDA evaluate each contractor's production readiness, facility validation status, and capacity to meet potential emergency manufacturing demands. All responses should reference U.S.-based facilities where possible, consistent with the program's preference for domestic manufacturing capability.